GlassScriptPhysician profile
Clement Aluyi
NPI 1447459607
$12,350.84
in general payments reported to CMS, 2019-2025
51 companies · $1,880 in 2025
The $1,880 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $1,510 · 2021: $2,135 · 2022: $1,888 · 2023: $2,380 · 2024: $1,702 · 2025: $1,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,862 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,861.78 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,811.33 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,451.40 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $765.85 | 2019-2025 | |
| Lilly USA, LLC | $705.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $660.30 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $595.31 | 2021-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $538.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $489.41 | 2020-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $455.82 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.75 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $367.08 | 2020-2023 | Verquvo, Belsomra, Lagevrio |
| E.R. Squibb & Sons, L.L.C. | $364.46 | 2019-2025 | Cobenfy |
| Amgen INC. | $360.88 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $335.19 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $270.44 | 2019-2023 | Xarelto |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.22 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $203.53 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $185.88 | 2019-2022 | |
| Alkermes, INC. | $172.72 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $163.35 | 2022-2025 | Auvelity, Symbravo |
| Dexcom, INC. | $147.69 | 2021-2023 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $138.01 | 2024-2025 | Fanapt, Hetlioz |
| Aimmune Therapeutics, INC. | $135.80 | 2024-2025 | Zenpep |
| Lundbeck LLC | $113.15 | 2024-2025 | Rexulti, Vyepti |
| Scilex Pharmaceuticals INC. | $96.31 | 2022 | |
| Insulet Corporation | $95.54 | 2023-2025 | Omnipod |
| Nestle Healthcare Nutrition INC. | $93.40 | 2021-2023 | |
| Gilead Sciences, INC. | $91.56 | 2021-2023 | Epclusa |
| Exact Sciences Corporation | $90.04 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $86.43 | 2022-2025 | Minimed 780g, Inceptiv |
| Sunovion Pharmaceuticals INC. | $85.80 | 2019-2022 | |
| Medtronic Minimed, INC. | $60.25 | 2020 | |
| Phathom Pharmaceuticals, INC. | $57.96 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $54.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.84 | 2019-2020 | |
| Averitas Pharma INC. | $40.83 | 2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $36.57 | 2022-2025 | Austedo Xr |
| Corcept Therapeutics | $34.72 | 2024-2025 | Korlym |
| Neurocrine Biosciences, INC. | $33.71 | 2024 | Ingrezza |
| Allergan, INC. | $27.94 | 2019-2020 | |
| Qorumpartners | $26.13 | 2022 | |
| Eisai INC. | $25.33 | 2020-2021 | |
| Boston Scientific Corporation | $23.81 | 2025 | Watchman Access System |
| Biohaven Pharmaceutical Holding Company LTD. | $22.93 | 2022 | |
| Abbott Laboratories | $22.55 | 2023 | Proclaim |
| Viatris Specialty LLC | $22.30 | 2025 | Yupelri |
| Vertex Pharmaceuticals Incorporated | $20.90 | 2025 | |
| Indivior INC. | $19.00 | 2025 | Sublocade |
| Paratek Pharmaceuticals, INC. | $16.61 | 2025 | Nuzyra |
| Mylan Specialty L.P. | $14.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Aluyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.